Organization
Shanghai Vinnerna Biosciences
9 clinical trials
Clinical trial
An Open-label, Single-dose, Phase I Study to Assess the Pharmacokinetics and Safety of JT001 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2023-08-18
Clinical trial
The Mass Balance Study of [14C]JT001 in Chinese Healthy Adult Male SubjectsStatus: Recruiting, Estimated PCD: 2023-06-15
Clinical trial
A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19)Status: Terminated, Estimated PCD: 2022-12-15
Clinical trial
Effect of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese SubjectsStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
An Open-label, Dose-Escalation, Multiple-Dose Phase 1 Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets in Caucasian Healthy Subjects After Oral AdministrationsStatus: Withdrawn, Estimated PCD: 2022-08-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Non-Random, Open-label, Parallel-group Study to Assess the Pharmacokinetics of JT001 in Subjects With Mild and Moderate Renal Impairment Compared to Subjects With Normal Renal FunctionStatus: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Phase 1, Open-label, Single-and Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of JT001 Administered Orally in Elderly Chinese Subjects With Underlying DiseasesStatus: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Real-world Study：Disease Outcome and Safety of JT001 in Patients With Coronavirus Disease 2019 (COVID-19)Status: Recruiting, Estimated PCD: 2024-05-31